No price history available.
Key financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | SGDm | 218 | 348 | 436 | 445 | 528 | 440 | N/A | N/A |
| Operating profit | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | SGDm | 137 | 331 | 166 | -260 | 110 | 100 | N/A | N/A |
| EPS reported | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | SGDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | SGD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in SGD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Established in 1987, Ho Bee Land Limited operates as a real estate firm. Since its listing on the Singapore Exchange Mainboard in 1999, the company has expanded its presence internationally, with interests across Australia, China, the United Kingdom, and Europe. From its beginnings, its diverse portfolio has encompassed high-quality residential, commercial, and advanced industrial developments. Within Singapore, Ho Bee is widely acclaimed as the trailblazing developer of premium residences in the prestigious Sentosa Cove district. Significant projects in its home market also feature The Metropolis at one-north, currently the largest Grade A office complex located beyond the Central Business District, alongside Elementum, an innovative biomedical sciences facility anticipated for completion by the close of 2023. Its London holdings comprise eight investment properties, among them prominent addresses such as The Scalpel, Ropemaker Place, and 1 St Martin's Le Grand. The firm is dedicated to providing superior homes and structures for its stakeholders and fostering a sustainable built environment.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
Established in 1987, Ho Bee Land Limited operates as a real estate firm. Since its listing on the Singapore Exchange Mainboard in 1999, the company has expanded its presence internationally, with interests across Australia, China, the United Kingdom, and Europe. From its beginnings, its diverse portfolio has encompassed high-quality residential, commercial, and advanced industrial developments. Within Singapore, Ho Bee is widely acclaimed as the trailblazing developer of premium residences in the prestigious Sentosa Cove district. Significant projects in its home market also feature The Metropolis at one-north, currently the largest Grade A office complex located beyond the Central Business District, alongside Elementum, an innovative biomedical sciences facility anticipated for completion by the close of 2023. Its London holdings comprise eight investment properties, among them prominent addresses such as The Scalpel, Ropemaker Place, and 1 St Martin's Le Grand. The firm is dedicated to providing superior homes and structures for its stakeholders and fostering a sustainable built environment.